Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Altimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated ...

Altimmune, Inc.'s pemvidutide shows promising results in MASH resolution and weight loss, paving the way for phase 3 trials.

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

About the IMPACT Study The IMPACT (NCT05989711) trial enrolled 212 patients with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive either weekly ...

Rivus Pharmaceuticals’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the ...

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis ...

Conshohocken, Pennsylvania Monday, June 23, 2025, 13:30 Hrs [IST] ...